Quick Takeaways
- Vestal Point Capital, LP filed SCHEDULE 13G for Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share (LXEO).
- Disclosed ownership: 6%.
- Date of event: 30 Jun 2025.
Vestal Point Capital, LP - 30 Jun 2025 SCHEDULE 13G Report for Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share (LXEO)
- Filing Manager
- Vestal Point Capital, LP
- Reporting Manager
- Vestal Point Capital, LP
- Symbol
- LXEO
- Shares outstanding
- 53,802,683 shares
- Disclosed Ownership
- 3,228,161 shares
- Ownership
- 6%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Aug 2025, 15:51:10 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Vestal Point Capital, LP disclosed 6% ownership in Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share (LXEO) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 15:51.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vestal Point Capital, LP | 6% | 3,228,161 | 0 | 3,228,161 | /s/ Ryan Wilder | By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner | |
| Ryan Wilder | 6% | 3,228,161 | 0 | 3,228,161 | /s/ Ryan Wilder | Ryan Wilder, Individually |